On April 30, the University of California (UC) at Berkeley pressed its case to reverse a patent board decision in a high-stakes fight over intellectual property rights to the revolutionary gene-editing technology CRISPR-Cas9.
Study the topic in more depth in the AAPS book Challenges in Protein Product Development
To read the full content, please log in with your AAPS member username and password.
Sign InNot a member? Learn more and join today!
AAPS Newsmagazine helps pharmaceutical scientists excel in their jobs by providing current science, news, career advice, member recognition, AAPS offerings, and other valuable contemporary information.
2107 Wilson Blvd. #700
Arlington, VA 22201
AAPS Customer Service